

PRESS RELEASE



Hansa Biopharma to participate in two upcoming investor conferences

Hansa Biopharma has been invited to participate in two global biotech and healthcare conferences during March including Cowen Annual Health Care Conference in Boston and Carnegie Nordic Healthcare Seminar in Stockholm.

Lund, Sweden February 25, 2020. Hansa Biopharma, the leader in immunomodulatory enzyme technology for rare IgG mediated diseases, today announced that the Company's management team will participate in the following upcoming investor conferences:

- Cowen and Company's 40th Annual Health Care Conference in Boston on Monday, March 2, 2020, with a presentation at 4:10 PM EST/ 22:10 CET on the same day.
- The Carnegie Nordic Healthcare Seminar in Stockholm on Wednesday, March 4, 2020, with a presentation at 8:00 AM CET

A live webcast of the Cowen presentation will be available on the Events & Webcast page of the Company's website, www.hansabiopharma.com. A replay of the presentation will be available approximately two hours after the event and will be available for two weeks following the presentation.

Calendar 2020

Feb 27-28, 2020	Road Show Cowen, Chicago/Dallas
Mar 2, 2020	Cowen Annual Health Care Conference, Boston
Mar 4, 2020	Road Show Argot, New York City
Mar 4, 2020	Carnegie Nordic Healthcare Seminar, Stockholm
Mar 26, 2020	Kempen Expert Call with Prof. Mårten Segelmark on Anti-GBM
Apr 2, 2020	Annual Report 2019
Apr 21-22, 2020	Kempen Life Sciences Conference, Amsterdam
Apr 28, 2020	Interim Report Jan-Mar 2020
May 5, 2020	Annual General Meeting
May 18, 2020	UBS Global Healthcare Conference, NYC
May 19-20, 2020	RBC Global Healthcare Conference, NYC
May 26, 2020	ABG Life Science Summit, Stockholm
May 27, 2020	Ökonomisk Ugebrev Life Science Conference, Copenhagen
Jul 16, 2020	Interim Report Jan-Jul 2020
Sep 16-17, 2020	Bank of America Merrill Lynch Global Healthcare Conf., London
Oct 22, 2020	Interim Report Jan-Sep 2020

The information was submitted for publication, through the contact person set out below, at 08:00 a.m. (CET) on February 25, 2020.

Contact information

Klaus Sindahl
Head of Investor Relations
Hansa Biopharma
M: +46 (0) 709-298 269
E: klaus.sindahl@hansabiopharma.com

Rolf Gulliksen
Head of Corporate Communications
Hansa Biopharma
M: +46 (0) 733-328 634
E: rolf.gulliksen@hansabiopharma.com

About Hansa Biopharma

Hansa Biopharma is leveraging its proprietary immunomodulatory enzyme technology platform to develop treatments for rare immunoglobulin G (IgG)-mediated autoimmune conditions, transplant rejection and cancer.

The Company's lead product candidate, imlifidase, is a unique antibody-cleaving enzyme that potentially may enable kidney transplantation in highly sensitized patients with potential for further development in other solid organ transplantation and acute autoimmune indications. Imlifidase is currently under review for marketing authorization by EMA. Hansa's research and development program is advancing the next generation of the Company's technology to develop novel IgG-cleaving enzymes with lower immunogenicity, suitable for repeat dosing in relapsing autoimmune diseases and oncology.

Hansa Biopharma is based in Lund, Sweden and also has operations in Europe and US.

Hansa Biopharma
Scheelevägen 22
SE- 223 63 Lund, Sweden
Phone: +46 46 16 56 70
www.hansabiopharma.com

Nasdaq OMX Stockholm
Ticker: HNSA
ISIN: SE 0002148817